CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 403 enrolled
Drug / intervention
Azithromycin IVdrug
Likely dose
Azithromycin IV 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01671280
NCT01671280N/ACompleted

Drug Use Investigation Of Azithromycin Iv

Pfizer·observational·Posted Aug 23, 2012·Updated Apr 26, 2017

In Brief

An observational study evaluating Azithromycin IV for Pneumonia and Pelvic Inflammatory Disease. Completed, enrolled 403 participants.

Detailed Summary

To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2012
Enrollment StartSep 20, 2012
Primary CompletionApr 22, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.9 years ago

Interventions

Azithromycin IVdrug

The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy. The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.